Xencor (XNCR) Climbs +50.2% in 30 Days: Pipeline Updates and Royalty Resolution Fuel the Rally
Key Takeaways
- XNCR advanced approximately 50.2% in the 30-day period, rising from a $14.98 close on July 15, 2026, to roughly $22.50 in mid-August.
- The move accelerated after Xencor announced that Phase 1 expansion-cohort data for XmAb819 in advanced clear cell renal cell carcinoma was selected for an oral presentation at ESMO 2026.
- A $105 million agreement with Alexion resolved the U.S. Ultomiris royalty dispute, preserved ex-U.S. royalties, and extended Xencor's operating runway through 2028.
- Second-quarter 2026 results showed $51.2 million in revenue and a narrower net loss than the prior-year period, reinforcing the upward trend.
- Over the last quarter, XNCR climbed about 89.4% from an $11.88 close on May 14, 2026.
A Closer Look at Xencor (XNCR) and Its Market Position
Xencor, Inc. is a clinical-stage biopharmaceutical company focused on engineered antibodies for cancer and autoimmune diseases. Its XmAb technology platform modifies antibody structures to create new mechanisms of action, such as bispecific T-cell engagers and extended half-life antibodies. More than 20 XmAb-engineered candidates are in clinical development, with several partnered medicines already on the market. Key wholly owned programs include XmAb819 (ENPP3 x CD3) for advanced clear cell renal cell carcinoma, XmAb942 for ulcerative colitis, XmAb541 for gynecologic and germ cell tumors, and XmAb657 for idiopathic inflammatory myopathies. The company also earns collaboration, milestone, and royalty revenue from partners including Alexion, part of AstraZeneca (AZN), and Incyte (INCY). I find XNCR particularly interesting because of its mix of pipeline readouts and royalty-linked cash flows.
XNCR Stock Performance Over the Past 30 Days and Quarter
Closing prices show XNCR finished at $14.98 on July 15, 2026, and traded near $22.50 by mid-August, for a 30-day gain of about 50.2%. The stock hit a 52-week high of $23.34 on August 12 before pulling back modestly. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The quarterly picture is even stronger. XNCR closed at $11.88 on May 14, 2026, so the move to roughly $22.50 equates to an advance of approximately 89.4% over three months. Shares bottomed near $10.41 on May 19 before recovering through June and then accelerating sharply in July.
Catalysts Behind the Recent 30-Day Move
The first major driver came on July 17, when Xencor announced that Phase 1 expansion-cohort results for XmAb819 in advanced clear cell renal cell carcinoma had been accepted for a proffered paper oral presentation at the ESMO Congress 2026. That news supported dose selection for a planned pivotal study and triggered a single-session gain of roughly 17%.
Momentum carried forward, with XNCR reaching 52-week highs on July 20 and July 21 as investors reassessed the wholly owned oncology and autoimmune pipeline. Attention also turned to XmAb942, now advancing in the Phase 2b XENITH-UC trial in ulcerative colitis, with interim results expected near year-end 2026.
A second catalyst arrived on July 29, when Xencor agreed to receive $105 million from Alexion in two equal payments to settle the U.S. Ultomiris royalty dispute. The deal preserved royalties on ex-U.S. sales, and management indicated the operating runway now extends through 2028. XNCR closed at $21.49 on July 30.
On August 5, second-quarter results provided further fundamental support. Revenue reached $51.2 million, up from $43.6 million a year earlier, while net loss narrowed to $0.29 per share from $0.41. Xencor recognized $27.6 million in royalty revenue tied to the dispute period and guided to $420 million to $440 million in cash and marketable securities at year-end 2026.
What Powered the Stronger Quarterly Advance
The broader three-month rally reflects a shift in how the market is valuing Xencor’s pipeline and balance sheet. After falling to roughly $10.41 in mid-May, shares recovered as investors looked ahead to a data-rich second half of 2026 across oncology and autoimmune programs. The ESMO presentation acceptance for XmAb819, progress on XmAb942 in ulcerative colitis, and updates planned for XmAb541, plamotamab, and XmAb657 created a catalyst-rich backdrop. The Alexion resolution removed a significant royalty uncertainty while adding near-term cash, and the second-quarter report highlighted improving financial flexibility. Together, these elements turned a gradual recovery into a sharp re-rating.
Key Items on the Horizon for XNCR Investors
The next major catalyst is the ESMO Congress 2026, scheduled for October 23–27, where XmAb819 expansion-cohort data will be presented; the abstract is expected to be available October 18. Investors will also watch the Phase 2b XENITH-UC trial of XmAb942 in ulcerative colitis, with an interim update expected near year-end 2026, and second-half 2026 updates for XmAb541, plamotamab, and XmAb657. The planned first-in-human study of XmAb412 and the initial $52.5 million Alexion payment in August 2026 are additional near-term items. Broader factors include biotech sector sentiment, interest-rate expectations, clinical trial execution, and competitive developments in T-cell engagers and TL1A antibodies. These elements can influence volatility in either direction.
AI Tools in My Research Process
I often rely on Tickeron’s AI Trading Bots to test systematic approaches alongside my fundamental work. The platform offers hundreds of bots trading thousands of tickers, and the trending section highlights top-performing strategies that fit various timeframes and risk profiles. This gives me an extra lens when evaluating names like XNCR without replacing core analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
XNCR sees MACD Histogram just turned negative
XNCR saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on August 31, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 47 instances where the indicator turned negative. In 41 of the 47 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 87%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for XNCR moved out of overbought territory on August 28, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In 20 of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at 77%.
The Momentum Indicator moved below the 0 level on September 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XNCR as a result. In 61 of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XNCR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
XNCR broke above its upper Bollinger Band on August 18, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +1.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where XNCR advanced for three days, in 196 of 259 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Aroon Indicator entered an Uptrend today. In 151 of 190 cases where XNCR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. XNCR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 89 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.509) is normal, around the industry mean (18.959). P/E Ratio (0.000) is within average values for comparable stocks, (27.692). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.544). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (16.978) is also within normal values, averaging (426.575).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XNCR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of therapeutics to treat autoimmune and allergic diseases, cancer and other conditions
Industry Biotechnology
Advertisement